Skip to main content
SpringerLink
Log in

Nicht motorische Symptome bei Morbus Parkinson

Nonmotor symptoms in Parkinsonʼs disease

  • Neurologie
  • Published:
psychopraxis. neuropraxis Aims and scope Submit manuscript

Zusammenfassung

Nicht motorische Symptome bei Morbus Parkinson haben in den letzten Jahren als wesentliche Faktoren für die Lebensqualität der Patienten und deren Institutionalisierungen in späteren Krankheitsstadien zunehmend Beachtung in der Literatur gefunden. Sie treten in allen Krankheitsstadien auf. Häufig handelt es sich dabei um gastrointestinale Symptome, Blasenfunktionsstörungen, erektile Dysfunktion, orthostatische Hypotonie, Schlafstörungen, Depressionen, Demenz, Psychosen und medikamentös induzierte Verhaltensstörungen. Therapieempfehlungen werden in den Leitlinien der Österreichischen Parkinsongesellschaft und in einem rezenten Review der Movement Disorder Society nach derzeitige Datenlage und Evidenz zusammengefasst und präsentiert.

Abstract

Nonmotor symptoms in Parkinsonʼs disease have a high impact on quality of life. A broad range of symptoms can be found in all stages of the disease, including gastrointestinal symptoms,bladder problems, erectile dysfunction, orthostatic hypotension, sleep disturbances, depression, dementia, psychosis, and drug-induced behavioral changes. The guidelines of the Austrian Parkinson’s Disease Society and a recent review of the Movement Disorder Society provide therapy recommendations according to evidence-based data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Antonini A, Barone P, Marconi R et al (2012) The progression of non-motor symptoms in Parkinsonʼs disease and their contribution to motor disability and quality of life. J Neurol 259(12):2621–2631

    Article  PubMed  Google Scholar 

  2. Antonini A, Tesei S, Zecchinelli A et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinsonʼs disease and depression: effect on quality of life. Mov Disord 21(8):1119–1122

    Article  PubMed  Google Scholar 

  3. Braak H, Bohl JR, Müller CM et al (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinsonʼs disease reconsidered. Mov Disord Dec 21(12):2042–2051

    Article  Google Scholar 

  4. Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinsonʼs disease. Mov Disord 15 24(11):1641–1649

    Article  PubMed  Google Scholar 

  5. Barone P, Scarzella L, Marconi R et al (2006) Depression/Parkinson Italian study group. Pramipexole versus sertraline in the treatment of depression in Parkinsonʼs disease: a national multicenter parallel- group randomized study. J Neurol 253(5):601–607

    Article  PubMed  CAS  Google Scholar 

  6. Barone P, Poewe W, Albrecht S (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinsonʼs disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9 (6):573–580

    Article  PubMed  CAS  Google Scholar 

  7. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinsonʼs disease: diagnosis and management. Lancet Neurol 5:235–245

    Article  PubMed  Google Scholar 

  8. Chaudhuri KR, Martinez-Martin P, Odin P et al (2011) Handbook of non-motor symptoms in Parkinsonʼs disease. Springer, London

    Book  Google Scholar 

  9. Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) An international multicentre pilot study of the the first comprehensive self-completed non motor symptoms questionnaire for Parkinsonʼs disease: the NMSQuest study. Mov Disord 21:916–923

    Article  PubMed  Google Scholar 

  10. Cronin-Golomb A (2013) Emergence of nonmotor symptoms as the focus of research and treatment of Parkinsonʼs disease: introduction to the special section on nonmotor dysfunctions in Parkinsonʼs disease. Behav Neurosci 127(2):135–138

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Devos D, Dujardin K, Poirot I et al (2008) Comparison of desipramine and citalopram treatments for depression in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23(6):850–857

    Article  PubMed  Google Scholar 

  12. Diederich NJ, Goetz CG, Stebbins GT (2005) Repeated visual hallucinations inParkinsonʼs disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 20(2):130–140

    Article  PubMed  Google Scholar 

  13. Dubois B, Tolosa E, Katzenschlager R et al (2012) Donepezil in Parkinsonʼs disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 27(10):1230–1238

    Article  PubMed  CAS  Google Scholar 

  14. Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinsonʼs disease. N Engl J Med 351(24):2509–2518

    Article  PubMed  CAS  Google Scholar 

  15. Hussain IF, Brady CM, Swinn MJ et al (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinsonʼs disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71(3):371–374

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Lagalla G, Millevolte M, Capecci M et al (2006) Botulinumtoxin type A for drooling in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21(5):704–707

    Article  PubMed  Google Scholar 

  17. Litvinenko IV, Odinak MM, Mogil’naya VI et al (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinsonʼs disease (an open controlled trial). Neurosci Behav Physiol 38(9):937–945

    Article  PubMed  CAS  Google Scholar 

  18. Maricle RA, Nutt JG, Valentine RJ et al (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinsonʼs disease: a double-blind, placebo-controlled study. Neurology 45(9):1757–1760

    Article  PubMed  CAS  Google Scholar 

  19. Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinsonʼs disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11) 1623–1629

    Article  PubMed  Google Scholar 

  20. Menza M, Dobkin RD, Marin H et al (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10):886–892

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Ondo WG, Hunter C, Moore W (2004) A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinsonʼs disease. Neurology 62(1):37–40

    Article  PubMed  CAS  Google Scholar 

  22. Ondo WG, Levy JK, Vuong KD, Hunter C et al (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17(5):1031–1035

    Article  PubMed  Google Scholar 

  23. Pollak P, Tison F, Rascol O et al (2004) Clozapine in drug induced psychosis in Parkinsonʼs disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Rabinak, CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinsonʼs disease. Arch of Neurol 67(1) 58–63

    Article  Google Scholar 

  25. Rektorová I, Rektor I, Bares M et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinsonʼs disease: a national multicentre prospective randomized study. Eur J Neurol 10(4):399–406

    Article  PubMed  Google Scholar 

  26. Schoffer KL, Henderson RD, O’Maley K et al (2007) Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinsonʼs disease. Mov Disord 22(11):1543–1549

    Article  PubMed  Google Scholar 

  27. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinsonʼs disease? J Neurol Neurosurg Psychiatry 69:308–312

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Seppi K, Auff E, Haubenberger D et al (2013) Leitlinien zur Behandlung der Parkinson-Krankheit. Teil 2: Nichtmotorische Symptome. Neurologisch Suppl 2:1–21

    Google Scholar 

  29. Seppi K, Weintraub D, Coelho M et al (2011). The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinsonʼs disease. Mov Disord. Suppl 3:42–80

    Article  Google Scholar 

  30. Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80(9):800–809

    Article  PubMed  Google Scholar 

  31. Thomas A, Bonanni L, Gambi F et al (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404

    Article  PubMed  Google Scholar 

  32. Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinsonʼs disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99

    Article  PubMed  PubMed Central  Google Scholar 

  33. Witjas T, Kaphan E, Azulay JP et al (2002) Nonmotor fluctuations in Parkinsonʼs disease. Frequent and disabling. Neurology 59:408–413

    Article  PubMed  Google Scholar 

  34. Zangaglia R, Martignoni E, Glorioso M et al (2007) Macrogol for the treatment of constipation in Parkinsonʼs disease. A randomized placebo-controlled study. Mov Disord 22(9):1239–1244

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt

K. Wenzel gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Abt. für Neurogeriatrie, Universitätsklinik für Neurologie Graz, Auenbruggerpl. 22, 8036, Graz, Österreich

    K. Wenzel

Authors
  1. K. Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Wenzel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wenzel, K. Nicht motorische Symptome bei Morbus Parkinson. psychopraxis. neuropraxis 17, 23–26 (2014). https://doi.org/10.1007/s00739-014-0192-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00739-014-0192-3

Schlüsselwörter

Keywords

Search

Navigation